← Back to Search

Ultrasound

Ultrasound for Healthy Subjects

N/A
Waitlist Available
Led By John Pellerito, MD
Research Sponsored by John Pellerito
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Individuals without physical disabilities or conditions/diseases that may make them incapable of undergoing the study procedures or otherwise places them at a greater risk of harm
Individuals without significant past medical or surgical histories that would render them at a greater risk of harm
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the secondary outcome will be assessed approximately every 15 seconds during the approximately 10-minute ultrasound.
Awards & highlights

Study Summary

This trial is to see if organ-specific effects can be achieved by using low-energy sound waves on the spleen.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are able to understand and comply with the study procedures and you are not a person with a physical disability or condition/disease that may make you incapable of undergoing the study procedures or otherwise places you at a greater risk of harm.
Select...
You are not at a greater risk of harm.
Select...
You are between the ages of 18 and 45 years.
Select...
You are considered active as assessed by type of activity (i.e., walking, running, etc.) and number of hours a week performing the various activities.
Select...
You are able to attend all study visits at approximately the same time of day (i.e., 8 - 12 pm).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the secondary outcome will be assessed approximately every 15 seconds during the approximately 10-minute ultrasound.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the secondary outcome will be assessed approximately every 15 seconds during the approximately 10-minute ultrasound. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Anti-inflammatory Response
Secondary outcome measures
Transient Tissue Displacement

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: Group 6Experimental Treatment1 Intervention
Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
Group II: Group 5Experimental Treatment1 Intervention
Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
Group III: Group 3Experimental Treatment1 Intervention
Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Group IV: Group 2Experimental Treatment1 Intervention
Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Group V: Group 7Placebo Group1 Intervention
Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Group VI: Group 1Placebo Group1 Intervention
Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
Group VII: Group 4Placebo Group1 Intervention
Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ultrasound
2013
Completed Phase 1
~1950

Find a Location

Who is running the clinical trial?

John PelleritoLead Sponsor
General ElectricIndustry Sponsor
46 Previous Clinical Trials
12,260 Total Patients Enrolled
John Pellerito, MDPrincipal InvestigatorNorthwell Health
1 Previous Clinical Trials
27 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Northwell Health's The Feinstein Institute for Medical Research
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
~20 spots leftby Mar 2025